Open AccessA randomized controlled trial comparing primary tumour resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 (iPACS study)
Author(s) -
Konosuke Moritani,
Yukihide Kanemitsu,
Dai Shida,
Kohei Shitara,
Junki Mizusawa,
Hiroshi Katayama,
Tetsuya Hamaguchi,
Yasuhiro Shimada
Publication year - 2019
Publication title -
japanese journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.768
H-Index - 85
eISSN - 1465-3621
pISSN - 0368-2811
DOI - 10.1093/jjco/hyz173
Subject(s) - medicine , colorectal cancer , clinical endpoint , chemotherapy , randomized controlled trial , stage (stratigraphy) , oncology , cancer , clinical trial , surgery , paleontology , biology
It is controversial whether chemotherapy with or without primary tumour resection is effective for the patients with incurable Stage IV colorectal cancer. A randomized controlled trial, initiated in Japan in 2012, is being conducted to evaluate the survival benefit and safety of primary tumour resection plus chemotherapy compared with chemotherapy alone in asymptomatic Stage IV colorectal cancer patients with unresectable metastatic disease. Patients are randomly assigned to either chemotherapy alone or primary tumour resection followed by chemotherapy. The primary endpoint is overall survival. Secondary endpoints are progression-free survival, incidence of adverse events, proportion of patients with R0 resection and proportion of palliative surgery for the chemotherapy-alone group. This trial was registered in June 2012 with the UMIN Clinical Trials Registry as UMIN8147 [http://www.umin.ac.jp/ctr/index-j.htm]. In December 2017, the study protocol was amended for reducing sample size. A total of 280 patients will be enrolled over the course of 8.5 years.